ValuEngine upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a sell rating to a hold rating in a research note released on Tuesday.

A number of other equities analysts also recently commented on JUNO. Raymond James Financial, Inc. upgraded Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 price target for the company in a research note on Tuesday. Wedbush upgraded Juno Therapeutics from a neutral rating to an outperform rating and set a $42.00 price target for the company in a research note on Tuesday. Zacks Investment Research downgraded Juno Therapeutics from a hold rating to a sell rating in a research note on Monday. BTIG Research upgraded Juno Therapeutics from a sell rating to a neutral rating in a research note on Monday. Finally, Vetr upgraded Juno Therapeutics from a strong sell rating to a sell rating and set a $25.50 price target for the company in a research note on Monday, August 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $31.86.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at 43.81 on Tuesday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $44.60. The stock’s market capitalization is $4.60 billion. The firm has a 50-day moving average price of $28.62 and a 200-day moving average price of $25.14.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.24. The business had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm’s revenue was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share. On average, equities research analysts forecast that Juno Therapeutics will post ($3.13) earnings per share for the current year.

WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/juno-therapeutics-inc-juno-upgraded-by-valuengine-to-hold/1530841.html.

In other Juno Therapeutics news, Director Anthony B. Evnin purchased 9,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were bought at an average price of $24.40 per share, with a total value of $219,600.00. Following the completion of the acquisition, the director now owns 66,301 shares in the company, valued at approximately $1,617,744.40. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the sale, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,053,500 shares of company stock valued at $217,594,440. 15.26% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. M&T Bank Corp acquired a new stake in Juno Therapeutics during the first quarter worth $381,000. Nisa Investment Advisors LLC acquired a new stake in Juno Therapeutics during the first quarter worth $200,000. Laurion Capital Management LP acquired a new stake in Juno Therapeutics during the first quarter worth $390,000. Marshall Wace LLP acquired a new stake in Juno Therapeutics during the second quarter worth $1,071,000. Finally, Geode Capital Management LLC boosted its stake in Juno Therapeutics by 8.9% in the first quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock worth $13,206,000 after buying an additional 48,516 shares during the period. 70.76% of the stock is currently owned by institutional investors.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.